PONTE VEDRA, Fla., Nov. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets' Nineteenth (19) Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL on Monday, December 4 at 4:00 p.m. Eastern time. There is also the opportunity to meet the management at a breakout session scheduled immediately following the presentation.

A high-definition video webcast of the presentation will be available the following day on the Company's website at www.cadrenal.com/investors, and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: www.nobleconference.com and on Channelchek www.channelchek.com the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.

ABOUT CADRENAL THERAPEUTICS, INC.

Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions who require chronic anticoagulation. Tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) with atrial fibrillation (AFib), and also is being evaluated for the treatment of heart disease in patients with implanted medical devices such as left ventricular assist devices (LVADs), as well as in patients with antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolic pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin) used in the prevention of thrombosis. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.  

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.